

Investors Yawn at Latest Citron Jab, Send Intuitive Surgical Shares Up

Mass Device

Investors ignore a 3rd negative report from short-seller Citron Research on medical device company Intuitive Surgical, sending shares up slightly today.



Investors, who sent shares of [Intuitive Surgical](#) [1] (NSDQ:[ISRG](#) [2]) down 10% the 1st time Citron Research issued a negative report on the medical device company, yawned today at a 3rd missive from the short seller.

ISRG shares were up slightly as of about 3:30 p.m. today to \$561.07 apiece, despite Citron's repeated assertion that the stock is headed for \$300 per share.

Citing a [study and accompanying editorial](#) [3] published yesterday in the *Journal of the American Medical Assn.* questioning whether robot-assisted hysterectomy using a device like Intuitive's da Vinci surgical robot is worth its extra cost, the latest Citron broadside warns investors that the stock is significantly over-valued.

Source URL (retrieved on 01/29/2015 - 6:30pm):

http://www.mdtmag.com/news/2013/02/investors-yawn-latest-citron-jab-send-intuitive-surgical-shares?qt-recent_content=0

Links:

[1] <http://www.massdevice.com/company/intuitive-surgical-inc>

[2] <http://www.google.com/finance?q=isrg>

[3] <http://www.massdevice.com/news/robot-assisted-hysterectomy-worth-extra-cost-massdevicecom-call>